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Obstructive pulmonary disease is a multifactorial condition deriving from the interaction of environmental and 
genetic factors. From biochemical knowledge of the basis of the disease, al-antitrypsin and al-antichymotrypsin 
are considered two likely candidate genes. We therefore designed an association study comprising 232 unrelated 
Italian individuals divided as follows: 89 individuals with obstructive lung disease (66 with COPD and 23 with 
disseminated bronchiectasis) and 143 controls (45 patients with non-obstructive lung disease and 98 healthy 
individuals). We screened for Taq I (G1237A) polymorphism of the al-antitrypsin gene as well as the rare variants 
Bonn-l (Pro229Ala), Bochum -1 (Leu55Pro), Isehara-1 (Met389Val) and Isehara-2 (1258delAA), and the common 
signal peptide polymorphism Thr-15Ala of the al-antichymotrypsin gene. The frequencies of Taq I G1237A alleles 
were 1 I .7 and IO.8 % in obstructed patients and controls, respectively (P = 0.43 ), while those of signal peptide 
Thr-15Ala alleles were 51.6 and 50.3 % in obstructed patients and controls, respectively (PzO.42). We conclude 
that al-antitrypsin Taq I polymorphism and al-antichymotrypsin Thr-15Ala mutation are not major genetic risk 
factors for the development of obstructive lung disease in Italian patients. The al-antichymotrypsin rare variants 
were not detected: our results do not exclude the possibility that other al-antichymotrypsin gene mutations might 
be present in Italian obstructed patients but, if so, these genetic defects must be rare. 
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Introduction 
Established risk factors for obstructive pulmonary disease 
(OPD), including chronic obstructive pulmonary disease 
(COPD) and disseminated bronchiectasis of unknown 
origin, are cigarette smoking, environmental and occupa- 
tional exposure to dust and gases, and inherited al- 
antitrypsin (al-AT) deficiency (1). Cal-antitrypsin deficiency 
is the only established genetic risk factor for COPD and it 
has been clinically ascertained to be involved in no more 
than 2% of the total cases of COPD (2). In the large 
majority of individuals with COPD, environmental factors 
are thought to be responsible for the greatest contribution 
to the development of the disease. However, based on the 
evidence that only a minority of heavy smokers develop 
disabling airflow limitation and that COPD aggregates in 
families, though without a Mendelian pattern of inheri- 
Received 30 October 1998 Accepted in revised from 26 May 1999. 
Correspondence should be addressed to: Dr Maurizio Luisetti, 
Laboratorio di Biochimica e Genetica, Clinica di Malattie 
dell’Apparato Respiratorio, Universita degli Studi di Pavia, 
IRCCS Policlinico San Matteo, Via Taramelli 5, 27100 Pavia, 
Italy. Fax: (f 39) 382-502269; E-mail: luisetti@telnetwork.it 
0954-6111/99/090648+07 $12.00/O 
tance, these factors are likely to act upon a predisposing 
genetic background (3). 
Based on the limited knowledge of the biochemical basis 
of the disease, a number of putative candidate genes 
for OPD may be postulated (3-6). The most accreditated 
hypothesis for the development of COPD is an imbalance 
between proteinases and their naturally occurring inhibi- 
tors. This hypothesis deals with the crucial role played 
by the ability of neutrophil-derived serine proteinases,such 
as neutrophil elastase or cathepsin G, to produce the 
bronchial and lung features of chronic bronchitis and 
emphysema (7-9). The injury may be due to the inheri- 
ted or acquired deficiency of the inhibitors al-AT, 
the preferential inhibitor for neutrophil elastase, and 
alphal-antichymotrypsin, the preferential inhibitor for 
cathepsin G. These proteins belong to a superfamily of 
inhibitors called sevpins (serine proteinase inhibitors), 
encoded by a gene cluster mapping on the long arm of 
human chromosome 14. 
The inherited deficiency of al-AT is due to the expression 
of the defective al-AT variants 2 or Null in homozygosity 
or in compound heterozygosity (10). The defective S variant 
is a significant risk factor for COPD only when it is present 
in smoking individuals heterozygous for the defective Z 
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variant, even in the presence of plasma levels of al-AT 
exceeding 11 uM (11). With reference to the multifactorial 
form of COPD, the G1237A mutation in the 3’ flanking 
region of the al-AT gene has been described, which occurs 
at a significantly higher frequency among patients with 
COPD and bronchiectasis than among controls (12,13). 
Interestingly, this mutation, also called Taq I polymorph- 
ism, is not accompanied by any al-AT plasma deficiency. 
In marked contrast, Sandford et al. (14) have shown more 
recently that the Taq I polymorphism occurs with the same 
frequency in Canadian patients with airway obstruction 
and in non-obstructed controls. The frequencies of al-AT 
gene Taq I polymorphism in individuals with COPD 
outside England, Germany and Canada are not known. 
The role of al-antichymotrypsin in COPD is much 
less well defined than that of al-AT. The protein is 
an important acute-phase reactant and its physiological 
regulatory role is probably not sufficiently recognized. 
In contrast to al-AT, no homozygous deficiency is known 
for al-antichymotrypsin, thus suggesting that such a defect 
might be lethal (15). Partial hetero-zygous deficiency has 
been associated with increased residual volume values (16). 
Two rare mutations in the al-antichymotrypsin gene 
(Bochum-1 and Bonn-l) have been described as occurring 
occasionally in German COPD individuals (17); both 
variants were associated in carriers with plasma levels of 
al-antichymotrypsin corresponding to 79-59% of normal 
values. Other variants in the al-antichymotrypsin gene 
have been described in Germans (Thr-15Ala) with normal 
protein levels (17) and in the Japanese population (Isehara- 
1 and Isehara-2) (18). No data are available on the 
frequency of the Isehara-1 and -2 mutations in a COPD 
population. 
Methods 
STUDY DESIGN AND SUBJECTS 
Our investigation was designed as an association study, 
consisting of unrelated individuals recruited from the same 
geographical area (Pavia, Northern Italy). All individuals 
were white Caucasians of Italian descent. 
Obstructed patients 
A total of 89 consecutive obstructed patients admitted to or 
seen in the clinics of the Clinica di Malattie dell’Apparato 
Respiratorio of the IRCCS Policlinico San Matte0 of Pavia 
were enrolled. The obstructed patients consisted of 66 
patients (60 men and six women) with COPD and 23 
patients (11 men and 12 women) with disseminated 
bronchiectasis of unknown origin. 
The diagnosis of COPD was made according to the 
American Thoracic Society (ATS) standards (19). COPD 
patients were enrolled on the basis of an irreversible airflow 
obstruction, defined as a forced expiratory volume in 1 s 
(FEVi) of less than 70% and less than 12% reversible. 
Subjects with history of bronchial hyperresponsiveness, 
wheezing and atopy were excluded from the study. Thirty- 
six patients were former smokers, 20 were current life-long 
smokers and 10 had never smoked. Nine patients had 
familial aggregation of respiratory symptoms. The mean 
age of onset of respiratory symptoms was 46.6 + 16.5 
years. High resolution CT-scan revealed findings consis- 
tent with panacinar emphysema in 29 out of 66 patients, 
whereas centriacinar emphysema of varying severity 
was found in 37 subjects. In order to avoid including 
obstructed patients with an inherited al-AT deficiency, 
the plasma al-AT level, using a standard nephelometric 
assay, and the al-AT genotype for the Z and S alleles 
(see below ) were determined. 
The diagnosis of disseminated bronchiectasis involv- 
ing more than one lobe was based on high resolution 
CT-scan appearance or bronchographical features. In 
the same way, patients with bronchiectasis were excluded 
from the COPD group.The origin of the bronchiectasis 
was considered to be unknown as the patients had normal 
levels of immunoglobulins and al-AT and a negative sweat 
test. One patient with bronchiectasis was a current smoker, 
three were former smokers and 19 had never smoked. 
The mean age of onset of respiratory symptoms was 22.9 + 
21.2 years. Familial aggregation of respiratory symptoms 
was demonstrated in seven of the 23 bronchiectasis 
patients. 
Controls 
A total of 143 controls were studied. The first group 
consisted of 45 unrelated consecutive patients with 
non-obstructive pulmonary disease (NOPD) admitted 
to or seen in the clinics of the Clinica di Malattie 
dell’Apparato Respiratorio of the IRCCS Policlinico 
San Matte0 of Pavia. This group included patients with 
lung cancer (26 patients), TB (four patients), sarcoidosis 
(eight patients), pulmonary infections (five patients) and 
pneumothorax (two patients).This group of subjects 
represented a ‘positive control’, i.e. subjects with a 
pulmonary disease not likely to be influenced by any 
of the genes under investigation. Pulmonary function tests 
and high resolution CT-scan were performed to assess 
the underlying condition, thus excluding the presence of 
airflow obstruction and bronchiectasis. Seventeen patients 
were current smokers, 18 were former smokers and 10 had 
never smoked. 
The second control group was composed of 98 healthy 
unrelated volunteers recruited from the clinical staff. 
Regular medical survey data, including questionnaire, 
blood and urine chemistry, chest X-ray and pulmonary 
function tests, excluded any diseases and obstructive disease 
in particular. The @l-AT plasma level and genotype were 
assessed to avoid including asymptomatic subjects with 
inherited al-AT deficiency. All patients gave informed 
consent prior to entering the study, which was approved by 
the local Ethical Committee. The pulmonary characteristics 
of the 232 individuals enrolled are summarized in Table 1. 
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GENETIC ANALYSES 
Genetic analyses were performed at the Istituto di Biologia 
e Genetica, Universita di Verona. Genomic DNA was 
prepared from peripheral blood samples by standard 
methods (20). Polymerase chain reaction (PCR) amplifica- 
tion of genomic DNA was performed using Perkin- Elmer 
DNA Thermal Cyclers (9600 or 2400). We added 5.25 pmol 
of each primer (reported in Table 2) and 0*2 U Taq DNA 
polymerase (HT, Cambridge, U.K.) to 100 pg of DNA in a 
25 ~1 final volume of a solution containing 50 mM KCl, 10 
mM Tris-HCI pH 8.3, 200 PM of each dNTP and 1.5 mM 
MgC12. Temperature cycling conditions were as follows: 
initial 5 min denaturation at 94°C) 30 cycles of 30 s at 94°C 
30 s at the annealing temperature specific for each pair of 
primers (Table 2), 30 s at 72°C and a final extension for 3 
min at 72°C. Table 3 reports the list of the xl-AT and 
al-antichymotrypsin polymorphisms and mutations inves- 
tigated and the pertinent restriction fragment length 
polymorphism (RFLP) conditions. 
STATISTICAL ANALYSIS 
Clinical data are presented as mean values & SD. Fre- 
quencies of mutations were counted using the number of 
alleles and are expressed as percentages. Frequencies were 
compared with Fisher’s exact test. Differences were 
considered statistically significant when the P-value was 
less than 0.05 on a two-sided test. The population size in 
this study had enough statistical power to detect an allele 
which imparted an odds ratio of 3.0, given a 10% 
prevalence for the Taq I polymorphism, or a 50% 
prevalence of the signal peptide polymorphism in the 
obstructed population. 
TABLE 1. Characteristics of the population studied. Mean values are shown FSD 
Patients Age FEVt FEVt/FVC 
(n> M/F (years) (% pred.) (% pred.) 
Obstructed 
COPD 66 6016 65.7 * 13.9 42.3 i 25.3 61.5* 16.1 
Diffuse Be 23 1 l/l2 53.6 l 15.8 58.7 i 22.5 86.1 i 12.8 
Controls 
NOPD 45 32,‘13 53.1* 18.5 87.2 i 17.3 90.3 * 15.8 
Healthy 98 54144 48.7h22.3 97.6*5.1 98.516.3 
M/F, Males/females; Be, bronchiectasis; NOPD, non-obstructive pulmonary disease; FVC, forced vital capacity. 
TABLE 2. PCR amplification conditions 
PCR primers Amplification Annealing 
Mutation 5’13’ product (bp) temperature (“C) 
G1237A ACTGTCTAACCACTCACTGT (D) 136 50 
ACAGTCGGTATCCATTGAT (R ) 
Glu342Lys (Z) ATAAGGCTGTGCTGACCATCGTC (D) 179 51 
TTGGGTGGGATTCACCACTTTTC (R ) 
Glu264Val (S) TGAGGGGAAACTACAGCACCTCG (D) 121 50 
AGGTGTGGGCAGCTTCTTGGTCA (R ) 
Pro229Ala TATGAGGACTCTGGGCACTTC (D) 366 50 
ACTCCAGAGAGTCTCTCCAC (R ) 
Leu55Pro TCCATCTGGCCCTCTGAGACT (D) 787 56 
CTCTACAGTGGTTTGCCTAATAAC (R ) 
Thr-15Ala TCCATCTGGCCCTCTGAGACT (D) 156 56 
GGGTCAGATTCTCCTCGTCAA (R ) 
Met389Val CATAAGGCTGTGCTTGATGTA (D) 230 55 
TTACTGAGAGCCCCACTGCATGAT (R ) 
1258delAA CATAAGGCTGTGCTTGATGTA (D) 230 55 
TTACTGAGAGCCCCACTGCATGAT (R ) 
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Results 
With reference to the al-AT Taq I polymorphism, we could 
not detect any significant deviation in the frequency of 
the G1237A allele (Fig. 1) between obstructed patients 
(11.7%) and controls (10.8%; P=O.43). Among obstrnc- 
ted patients, there was no difference in the distribution 
of the G1237A allele between COPD and bronchiectasis 
groups, the frequencies being 11.3% and 13%, respectively. 
One patient from the COPD group and one patient 
from the bronchiectasis group carried the mutation 
as a homozygote (G1237A/G1237A ), whereas all other 
patients in the obstructed and control groups were 
G1237A/-. 
With reference to al-antichymotrypsin common signal 
peptide polymorphism, the distribution of the Thr-15 Ala 
allele (Fig. 2) was not significantly different between 
obstructed patients and controls: (51.6% and .50.3%, 
respectively; P==O*42). The distribution in the subsets 
was as follows: COPD, 53.7%; bronchiectasis, 45.6 %; 
TABLE 3. Restriction fragment length polymorphism (RFLP) analysis conditions 
Mutation 
Restriction Common allele Rare allele 
enzyme (bp) (b) 
al-AT gene 
G1237A 
Glu342Lys (Z) 
Glu264Val (S) 
al-antichymotrypsin gene 
Pro229Ala 
Leu55Pro 
Thr-15Ala 
Met389Val 
1258delAA 
Taq I 71, 65 136 
Taq I 157, 22 179 
Taq I 100, 21 121 
Alu I 
Dde I 
BstN I 
BspH I 
BsPH I 
227, 139 
282, 154, 100, 77, 71, 57, 36 
156 
164, 66 
164, 66 
207, 139, 20 
382, 154, 77, 71, 57, 36 
87, 69 
230 
164, 64 
M 1 2 3 4 5 6 I 
I  
-  
-  
136 bp 
FIG. 1. G1237A (Taq I) polymorphism of the ccl-antitrypsin (al-AT) gene. Electrophoresis in 3.5% (w/v) agarose gel of the 
amplification product. Lanes l-3,5,6 : normal subjects. Lane 4 : subject heterozygous for the G1237A polymorphism. Lane 7 
: sample not incubated with Taq I restriction endonuclease. M : molecular weight marker @X/Hinf I. 
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non-obstructive pulmonary disease, 55.5%; and healthy 
controls 47.9. Rare cll-antichymotrypsin gene mutations, 
namely Bonn-l (Pro229Leu), Bochum-l(Leu55Pro), lse- 
hara-1 (Met389Val ) and Isehara-2 (1258delAA ), were not 
found in any group. All relevant results are summarized in 
Table 4. 
al-AT genotyping for common Z and S variants 
confirmed that no patients with inherited al-AT deficiency 
were included in the study (data not shown). 
Discussion 
When studying the genetic component of a multifactorial 
disorder, association studies with candidate genes, such as 
the present study, are limited by the fact that only known 
genes, which are thought to be involved in the pathogenetic 
processes, can be studied (27). In previous association 
studies we have been able to show, in the same groups of 
individuals, that the CFTR gene is not involved in the 
FIG. 2. Thr-15Ala polymorphism of the a-I-antichymotrypsin gene. Electrophoresis in 3% (w/v) agarose gel of the 
amplification product. Lanes 1,3,6: heterozygous subjects. Lanes 2,4: subjects homozygous for the Ala allele. Lane 5: subject 
homozygous for the Thr allele. Lane 7: sample not incubated with BstN I restriction enzyme. M: 
molecular weight marker V. 
TABLE 4. Mutations in the serpin genes 
Gene Mutation 
Obstructed Controls 
COPD Be NOPD Healthy 
(132 alleles) (46 alleles) (90 alleles) (196 alleles) 
aAT 
@l-Achy 
Taq I 
(G1237A) 
Signal peptide 
(Thr- 15Ala) 
Bonn- 1 
(Pro229Ala) 
Bochum- 1 
(Leu55Pro) 
Isehara-1 
(Met389Val) 
Isehara-2 
(1258delAA) 
15/132 (11.3%) 6/46 (13%) 9/90 (10%) 22/196 (11.2%) 
71/132 (53.7%) 21146 (45.6%) 50/90 (55.5%) 94/196 (47.9%) 
0 0 0 0 
0 0 0 0 
0 0 0 0 
0 0 0 0 
Al-Achy, ccl-antichymotrypsin. 
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pathogenesis of COPD (28), but that it is significantly 
associated with the occurrence of disseminated bronchiec- 
tasis of unknown origin (4,29). For this reason, we decided 
to perform our genetic investigation of airflow obstruction 
not only in COPD individuals, but also in bronchiectatic 
patients. 
The serpin genes al-AT and al-antichymotrypsin have 
strong potential as candidate genes for COPD based on 
current knowledge of the biochemical basis of the disease 
(7). With reference to the al-AT gene, our aim was to focus 
on Gl237A allele frequency, as this has been previously 
indicated as a significant risk factor for COPD and 
bronchiectasis in relatively small population samples. 
This mutation is particularly interesting as, although it is 
not associated with a deficiency in plasma al-antitrypsin, it 
has been suggested to occur in a regulatory sequence of the 
3’ flanking region of the gene, thus affecting ul-antitrypsin 
gene expression during inflammation (21,30). However, 
evidence that the Gl237A allele has no effect on the plasma 
cli-antitrypsin level during inflammatory response in 
patients with cystic fibrosis (31) casts doubt on whether it 
might play a significant role in vivo. Kalsheker et al. (12,32) 
found that the Gl237A allele was present in 28 out of 140 
(20%) U.K. patients with either emphysema or bronchiec- 
tasis, but in only 4.9% of healthy controls. Poller et al. (13) 
found a slightly lower frequency in Germans with COPD: 
15.3 vs. 5.4% in controls. Our data do not support these 
findings, as the Gl237A alelle frequency in obstructed 
patients and control subjects was not different, as also 
found by Sandford et al. (14). The allele frequency found in 
our controls was 10.8% overall; 10% in non-obstructive 
pulmonary disease individuals and 11.2% in healthy 
individuals. This is higher than that found in some other 
studies (12,13,14,32). However, ethnic differences may 
explain these discrepancies, at least in part as the G1237A 
allele frequency has been reported to vary markedly among 
populations. For example, its frequency ranges from 24.1 
and 23.5% in black South Africans and Kuwaiti Arabs, 
respectively, to 6 and 2.7% in white South Africans and 
Russians, respectively (33,34). 
As stated previously, the role of ml-antichymotrypsin in 
the pathogenesis of COPD is much less well defined than 
that of al-AT. As a consequence, the possible role of the 
al-antichymotrypsin gene has been less studied. The 
defective Pro229Ala (Bonn-l) and Leu55Pro (Bochum-1) 
variants have so far been found in only 4 and 1.5%, 
respectively, of German COPD patients, and none of 102 
Russian COPD patients showed the Pro229Ala variant 
(35). In a Canadian study, the Pro229Ala mutation was 
found in 0.6 % of obstructed patients and in 1.7% of non- 
obstructed patients, whereas the Leu55Pro mutation was 
not found (36). Similarly the Thr-15Ala allele of the signal 
peptide common polymorphism was frequent among Ger- 
man COPD patients and controls (28 and 35%, respec- 
tively). The Met389Val and 1258delAA variants (Isehara-1 
and Isehara-2, respectively) have so far only been reported 
in the Japanese population: four out of the six individuals 
carrying the Isehara-1 mutation had occlusive cerebro- 
vascular disease (25) thus suggesting a possible role in this 
condition, whereas the Isehara-2 mutation was found in 
three individuals with reduced plasma levels of al-antic- 
hymotrypsin but no history of liver or lung disease (26). We 
did not find any of the al-antichymotrypsin variants in our 
OPD individuals or in our control groups and the 
distribution of the Thr-15Ala allele did not differ between 
patient and control groups. 
In conclusion, our study of al-AT and ctl-antichymo- 
trypsin genes seems to suggest that the common and rare 
mutations considered here are not strong genetic risk- 
factors for the multifactorial form of OPD in Italian 
patients. However, we cannot exclude that other rare or so 
far unknown mutations in the al-antitrypsin and cll- 
antichymotrypsin genes may play a significant role. In 
addition, as a multifactorial disease probably derives from 
the interaction of multiple genes with multiple environ- 
mental factors (26) we cannot exclude the possibility that 
serpin genes might play a role in combination with other 
genes. In this framework, screening for other candidate 
genes in the same individuals with a clearly defined 
phenotype, may be a useful strategy to investigate whether 
a combination of genes exists whose epistatic interactions 
confer increased susceptibility to chronic airflow limitation. 
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